Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$2.14 – $2.64
40% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $42.23B | $64.95B | $61.67B | $69.01B | $70.79B | $75.52B | $74.99B | $75.45B |
| Cost of revenue | $32.16B | $52.08B | $51.23B | $55.78B | $57.51B | $61.33B | $62.47B | $63.99B |
| Gross profit | $10.07B | $12.87B | $10.44B | $13.23B | $13.28B | $14.19B | $12.52B | $11.46B |
| Gross margin | 23.8% | 19.8% | 16.9% | 19.2% | 18.8% | 18.8% | 16.7% | 15.2% |
| R&D | $585.5M | $576.5M | $611.9M | $874.7M | $819.5M | $782.1M | $763.8M | $591.9M |
| Operating income | $3.84B | $4.06B | $3.67B | $4.79B | $5.07B | $5.12B | $3.60B | $3.02B |
| EBITDA | $4.27B | $5.04B | $4.72B | $5.76B | $6.27B | $6.46B | $4.90B | $3.95B |
| Net income | $3.44B | $3.19B | $2.92B | $3.72B | $3.97B | $4.06B | $2.84B | $2.91B |
| Net margin | 8.1% | 4.9% | 4.7% | 5.4% | 5.6% | 5.4% | 3.8% | 3.9% |
| EPS (diluted) | 2.12 | 1.96 | 1.79 | 2.29 | 2.44 | 2.49 | 1.74 | 1.82 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $83.8B | $1.95 | $1.93–$1.97 | 1 |
| 2027 | $87.5B | $2.04 | $2.02–$2.06 | 1 |
| 2028 | $90.3B | $2.10 | $2.08–$2.13 | 1 |
Forward consensus · source: Financial Modeling Prep
GUANGZHOU PHARM CO ORD
No one on the platform currently holds GZPHF.
No tracked institution reports a position in GZPHF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-16 | $0.5162 | 2026-07-17 |
| 2025-09-02 | $0.4399 | 2025-09-26 |
| 2025-06-18 | $0.4362 | 2025-07-18 |
| 2024-10-17 | $0.4422 | 2024-11-15 |
| 2024-06-14 | $0.8227 | 2024-07-18 |
No one on the platform has traded GZPHF yet.
| +0.00% |
| $5.2B |
| — |
| HLUBFH. Lundbeck A/S | $5.50 | +0.00% | $5.8B | — |
| LVZPFLivzon Pharmaceutical Group Inc. | $5.22 | +0.00% | $6.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 1.4× earnings vs its 1.2× historical median P/E.
Fair value ≈ $1.94 · price $2.34 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.